Lorenzo Falchi

3.4k total citations · 1 hit paper
113 papers, 1.3k citations indexed

About

Lorenzo Falchi is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Lorenzo Falchi has authored 113 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Pathology and Forensic Medicine, 53 papers in Genetics and 53 papers in Oncology. Recurrent topics in Lorenzo Falchi's work include Lymphoma Diagnosis and Treatment (74 papers), Chronic Lymphocytic Leukemia Research (43 papers) and CAR-T cell therapy research (38 papers). Lorenzo Falchi is often cited by papers focused on Lymphoma Diagnosis and Treatment (74 papers), Chronic Lymphocytic Leukemia Research (43 papers) and CAR-T cell therapy research (38 papers). Lorenzo Falchi collaborates with scholars based in United States, Spain and United Kingdom. Lorenzo Falchi's co-authors include Srđan Verstovšek, Gilles Salles, Santosha A. Vardhana, Alessandra Ferrajoli, Michael J. Keating, William G. Wierda, Susan Lerner, Ahmed Sawas, Kate J. Newberry and Owen A. O’Connor and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lorenzo Falchi

103 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities

2022 110 citations Lorenzo Falchi, Gilles Salles et al. Blood profile →

Peers

Countries citing papers authored by Lorenzo Falchi

Since Specialization

Citations

This map shows the geographic impact of Lorenzo Falchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorenzo Falchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorenzo Falchi more than expected).

Fields of papers citing papers by Lorenzo Falchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorenzo Falchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorenzo Falchi. The network helps show where Lorenzo Falchi may publish in the future.

Co-authorship network of co-authors of Lorenzo Falchi

This figure shows the co-authorship network connecting the top 25 collaborators of Lorenzo Falchi. A scholar is included among the top collaborators of Lorenzo Falchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorenzo Falchi. Lorenzo Falchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma 2024 ·OncoImmunology ·(unknown), Alejandro Luna, Lorenzo Falchi	12
2	Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). 2024 ·Journal of Clinical Oncology ·Yasmin Karimi, Pau Abrisqueta, Sven de Vos, Marcel Nijland, Fritz Offner, (unknown), (unknown), (unknown), (unknown), Raúl Córdoba, Lorenzo Falchi	7
3	IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Lorenzo Falchi, Joost S.P. Vermaat, Gerardo Musuraca, Marcel Nijland, Jacob Haaber Christensen, Fritz Offner, Lori A. Leslie, Joshua Brody, Daniela Hoehn, (unknown), Liwei Wang, Jian Mei, David Belada, Pau Abrisqueta	1
4	CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas 2024 ·PubMed ·Paola Ghione, (unknown), Erel Joffe, M. Lia Palomba, Ariela Noy, Philip Caron, Paul A. Hamlin, Anita Kumar, Matthew J. Matasar, Colette Owens, Alison J. Moskowitz, Lorenzo Falchi, David J. Straus, Steven M. Horwitz, Gilles Salles, Ahmet Doǧan, Andrew D. Zelenetz	1
5	A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma. 2024 ·Journal of Clinical Oncology ·Lorenzo Falchi, Patricia Walker, (unknown), Gareth P. Gregory, (unknown), (unknown), Olivier Demaria, (unknown), (unknown), (unknown), Carine Paturel, Sonia Quaratino	1
6	ABCL-272 Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Pau Abrisqueta, Lorenzo Falchi, Marcel Nijland, Sven de Vos, Fritz Offner, (unknown), (unknown), (unknown), (unknown), Yasmin Karimi, Raúl Córdoba	1
7	Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial 2024 ·Blood ·Lorenzo Falchi, Anna Sureda, Sirpa Leppä, Joost S.P. Vermaat, Marcel Nijland, Jacob Haaber Christensen, Sven de Vos, Harald Holte, Reid W. Merryman, Pieternella J. Lugtenburg, (unknown), Kim Linton, (unknown), Christopher Morehouse, Andrew J. Steele, (unknown), Liwei Wang, Daniela Hoehn, Martin Hutchings, David Belada	5
8	Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma 2024 ·Haematologica ·Lorenzo Falchi, Martin Hutchings, Carmelo Carlo‐Stella, Franck Morschhauser, Michael Dickinson, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquín Martínez‐López, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppä, (unknown), (unknown), James Relf, (unknown), Linda Lundberg, Emmanuel Bachy	2
9	Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial 2024 ·Blood ·Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Raúl Córdoba, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Toshihiko Oki, Andrew J. Steele, Yi Hao, (unknown), (unknown), David Belada	7
10	Salvage Radiotherapy as a Bridge for Relapsed Secondary CNS Lymphoma 2023 ·International Journal of Radiation OncologyBiologyPhysics ·G. Cederquist, Kathryn R. Tringale, Carla Hajj, (unknown), Ram Rup Sarkar, Jennifer Ma, (unknown), (unknown), (unknown), (unknown), Lorenzo Falchi, Michael Scordo, Christian Grommes, Joachim Yahalom, Brandon S. Imber	1
11	CNS Radiotherapy As Bridging Prior to CAR T-Cell Therapy for Non-Hodgkin B-Cell Lymphoma 2023 ·Blood ·G. Cederquist, Javin Schefflein, Sean M. Devlin, Harper Hubbeling, Kathryn R. Tringale, Gunjan L. Shah, Ana Alarcón Tomás, Roni Shouval, Carla Hajj, (unknown), Parastoo B. Dahi, Richard J. Lin, Maria Lia Palomba, Miguel‐Angel Perales, Gilles Salles, Lorenzo Falchi, (unknown), Michael Scordo, (unknown), Brandon S. Imber	1
12	HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE 2023 ·Hematological Oncology ·Lorenzo Falchi, Michael Roost Clausen, Fritz Offner, Sven de Vos, Joshua Brody, Kim Linton, Sylvia Snauwaert, Raúl Córdoba, Jian Wu, (unknown), (unknown), (unknown), David Belada	2
13	Radiotherapy As an Effective Bridge for Relapsed/Refractory Secondary CNS Lymphoma 2023 ·Blood ·G. Cederquist, Kathryn R. Tringale, Carla Hajj, Harper Hubbeling, Jennifer Ma, (unknown), (unknown), Gilles Salles, (unknown), Michael Scordo, Lorenzo Falchi, (unknown), Brandon S. Imber	1
14	How we treat mature B-cell neoplasms (indolent B-cell lymphomas) 2021 ·Journal of Hematology & Oncology ·Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell, Erel Joffe	22
15	Global Cytopathology-Hematopathology Practice Trends 2021 ·American Journal of Clinical Pathology ·(unknown), Ronald Balassanian, Matthew C. Cheung, Lorenzo Falchi, Robert P. Hasserjian, Oscar Lin, Steven Long, Amy Ly, Joshua Menke, Eric Mou, Yasodha Natkunam, Roberto Ruiz‐Cordero, (unknown), (unknown), Kwun Wah Wen, Dita Gratzinger	2
16	A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma 2017 ·Blood ·Jennifer E. Amengual, (unknown), Jennifer Kimberly Lue, Ahmed Sawas, Changchun Deng, (unknown), (unknown), (unknown), Aishling M. Rada, (unknown), Codruța Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, (unknown), Lawrence Schwartz, Serge Cremers, Owen A. O’Connor	91
17	A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL) 2017 ·Blood ·Lorenzo Falchi, Jennifer Kimberly Lue, Jennifer E. Amengual, Ahmed Sawas, Changchun Deng, Enrica Marchi, (unknown), (unknown), (unknown), (unknown), Aishling M. Rada, (unknown), (unknown), Owen A. O’Connor	10
18	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics 2016 ·Clinical Cancer Research ·Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George A. Călin, Susan O’Brien, Stefan Faderl, Xuemei Wang, William G. Wierda, Katayoun Rezvani, James M. Reuben, Jan A. Burger, Michael J. Keating, Alessandra Ferrajoli	23
19	L’omicidio del medico 2015 ·Rivista di psichiatria ·Liliana Lorettu, Lorenzo Falchi, (unknown), Paolo Milia, (unknown), Alessandra Nivoli	2
20	Glucocorticoid-induced activation of caspase-8 protects the glucocorticoid-induced protein Gilz from proteasomal degradation and induces its binding to SUMO-1 in murine thymocytes 2010 ·Cell Death and Differentiation ·Domenico Vittorio Delfino, (unknown), (unknown), Silvia S. Pierangeli, Enrico Velardi, Stefano Bruscoli, Maria Paola Martelli, Valentina Pettirossi, Lorenzo Falchi, (unknown), Carlo Riccardi	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact